Weave Bio, a company specializing in AI-native regulatory automation solutions, announced it has secured a $20 million Series A funding round led by USVP. This latest investment brings the San Francisco-based company’s total capital raised to $36 million and will help it accelerate its product development and expand its commercial team.
The Weave Platform is a cloud-based solution built to redesign regulatory workflows and content management. Serving pharmaceutical companies, biotech firms, contract research organizations and regulatory consultants, it helps streamline the process for getting novel therapies from lab to market by automating data organization, document authoring, review, publishing and responding to health authority questions.
The funding will enable the company to cover the entire therapeutic regulatory lifecycle, including market applications and post-market updates. Weave Bio also plans to expand its global footprint into regions like Europe, Japan and Latin America. The company will also further advance its AI capabilities to provide insights and support better decision making throughout the drug development process.
